To gain initial insights regarding the mechanistic basis for targeting the MTA1/mTOR pathway, we first investigated the link between MTA1 and mTOR signaling in PC3M prostate cancer cells, which are known to have a PTEN-null status [34] and the highest MTA1 expression of all prostate cancer cell lines [8]. This evidence concerns the gene MTOR and prostate carcinoma.